Krakow, Poland – 14 October 2019 – Ryvu Therapeutics (WSE:RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced the appointment of Setareh Shamsili, M.D., Ph.D., to the Executive Management Board. Dr. Shamsili was appointed Chief Medical Officer of Ryvu Therapeutics in August 2019. Dr. Shamsili, a seasoned veteran, brings more than 20 years of clinical oncology and drug development experience to Ryvu.
Dr. Shamsili was the first Chief Medical Officer of Merus NV, where she brought two initial candidates to the clinic for development in acute myeloid leukemia and solid tumors. During her tenure at Merus through 2016, Dr. Shamsili was instrumental in providing support for successful fundraising activities and establishing strategic alliances. From 2006-2012, Dr. Shamsili served as Global Medical Leader Oncology at Astellas Pharma Global Development.
Prior to joining Ryvu, dr. Shamsili has been an independent industry consultant for a number of immuno-oncology companies in the U.S. and Europe, contributing to programs in various stages of development and therapeutic classes including small molecules, antibodies and cancer vaccines, with her latest position being the interim Chief Medical Officer at AxImmune, a U.S.-based immuno-oncology company.
Dr. Setareh Shamsili received her M.D. degree and board certification in internal medicine from the National University of Medical Sciences in Tehran, with a focus in oncology, and her Ph.D. in Oncology from the international Erasmus Medical University in Rotterdam. She recently also has completed the University of Pennsylvania Wharton Business School Global Strategic Leadership Program.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets. SEL120 is a selective CDK8 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia.